PCVX Add to watchlist
$56.74 +0.53 (+0.94%)
After Hours: $56.74 +0.00 (+0.00%)
Last updated: Jul 15, 2026 22:56
52-Week Range
$56.74
$29.08 $56.74 $65.00

Fundamentals Overview

Vaxcyte, Inc. is near the high of its 52-week range with moderate valuation, trading relatively flat today.

Valuation moderate

P/B 2.64

Risk (Beta)

1.22 — higher vol

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 58% confidence Risk: High Volatility — Beta 1.22. Consider smaller position size due to higher beta.

Pressures (Sell):

3M vs S&P 500: -18.1% · 3M vs Healthcare sector: -15.1%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$8.19B
P/E (TTM)
N/A
EPS (TTM)
N/A
Dividend Yield
N/A
52-Week Range
$29.08 - $65.00
Volume vs Avg
N/A
Beta
1.22

About

Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several ...
Sector: Healthcare
Headquarters: US
Employees: 507
IPO Date: Jun 2020
Website: vaxcyte.com
Beta: 1.22 (More volatile than market)

Ratings & Grades at a Glance

Overall rating: C. Current institutional positions: Buy: 28, Outperform: 2.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $-0.57; current price is $56.74. That’s a -101% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) N/A
PEG (TTM) N/A
P/B (TTM) 2.64
P/S (TTM) N/A
Liquidity & enterprise
Current Ratio (TTM) 7.49
Quick Ratio (TTM) 7.49
Cash Ratio (TTM) 1.08
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 0%
Gross margin (TTM) 0%
Operating margin (TTM) 0%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for PCVX.

Analyst Sentiment at a Glance

C
Buy 28Outperform 2
Consensus Target
$89.00
High Target
$89.00
Low Target
$89.00
Median Target
$89.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
BTIG maintain Buy Buy 2026-02-26
Guggenheim maintain Buy Buy 2026-02-02
BTIG maintain Buy Buy 2025-11-10
BTIG maintain Buy Buy 2025-10-16
Needham maintain Buy Buy 2025-04-08
Needham maintain Buy Buy 2025-04-01
B of A Securities maintain Buy Buy 2025-04-01
Goldman Sachs maintain Buy Buy 2025-04-01
Guggenheim maintain Buy Buy 2025-03-12
Needham maintain Buy Buy 2025-02-26
Guggenheim maintain Buy Buy 2025-02-26
BTIG maintain Buy Buy 2025-02-24
Needham maintain Buy Buy 2025-02-11
BTIG maintain Buy Buy 2024-12-24
Needham maintain Buy Buy 2024-11-06
Mizuho maintain Outperform Outperform 2024-09-10
B of A Securities maintain Buy Buy 2024-09-04
Jefferies maintain Buy Buy 2024-09-03
Needham maintain Buy Buy 2024-09-03
BTIG maintain Buy Buy 2024-09-03
Leerink Partners maintain Outperform Outperform 2024-09-03
Needham maintain Buy Buy 2024-08-07
BTIG maintain Buy Buy 2024-08-07
Needham maintain Buy Buy 2024-06-28
Needham maintain Buy Buy 2024-05-09
Needham maintain Buy Buy 2024-04-10
Mizuho maintain Buy Buy 2024-03-12
Needham maintain Buy Buy 2024-02-28
B of A Securities maintain Buy Buy 2024-01-02
Needham maintain Buy Buy 2023-11-07